News & Resources

Racial Disparities in Breast Cancer Survival Extend Beyond Socioeconomics

According to the World Health Organization, breast cancer is the most common malignancy worldwide and is a leading cause of cancer deaths. Racial disparities in breast cancer survival persist despite emphasis on early detection and availability of effective treatments. Reasons for this vary, but some possible factors include socioeconomic status, geographic residency, insurance coverage, and access to screening and care. In the United States, Black patients with breast cancer are 39% more likely to die of the disease than White patients, and this disparity is even higher in the state of Georgia, where it is estimated at 45%.

Dr Justin M. Luningham and colleagues analyzed patient records from 3 large Georgia health systems to measure the association of neighborhood deprivation with breast cancer mortality for 19,580 Black and White women. They analyzed associations among Area Deprivation Index (ADI), race, and mortality to elucidate factors contributing to disparities and inform community-level approaches to mitigate those disparities. The ADI is a percentile rank of socioeconomic disadvantage calculated from such indicators as income level, income disparity, educational attainment, employment, home values, and quality of life. Higher percentiles indicate areas with greater deprivation.

The results showed notable differences in mortality between racial groups, with deaths reported in 23.8% of Black women vs 15.9% of White women. The ADI was significantly associated with increased mortality among White women, but not among Black women. For White women, as ADI quartiles increased (ie, deprivation worsened), the rate of mortality also increased; however, for Black women, there were no significant changes in risk of mortality between ADI groups. The one exception to this was in the groups with highest deprivation, where there was no difference in mortality between Black and White women. On the basis of these findings, the authors suggested that ADI alone is insufficient to explain the observed racial disparities in breast cancer survival. Additional factors, such as built environment factors, residential segregation and lending bias, food landscape, unhealthy amenities, and access to health care, may not be fully captured by the ADI but may also be associated with increased breast cancer mortality.

Across Georgia, areas with high ADI had greater Black patient density and lower survival probability. Black women were more likely to be diagnosed with more advanced disease, while a higher proportion of White women were diagnosed with a grade 1 tumor (20.8% vs 12.5% for Black women). Lastly, the mean age at presentation was 3 years younger in Black patients across breast cancer subtypes. These findings suggest that ADI alone does not fully explain racial disparities in breast cancer survival. Therefore, further investigation is warranted to inform community-level approaches that may mitigate these disparities.

High level
This study demonstrated that ADI was associated with breast cancer mortality among White patients but not among Black patients. The authors suggested that current screening guidelines be adapted to recommend that Black women be screened at a younger age, since mean age at diagnosis was younger among Black patients in this study. The authors hypothesized that disparities in breast cancer survival outcomes may also be impacted by chronic stress and allostatic load, triggering epigenetic modifications that persist even when the stressor is removed and across generations. Further research is needed on possible epigenetic changes brought about by past and present neighborhood deprivation, as well as to increase understanding of other factors that contribute to racial disparities in breast cancer survival, especially among those living in the least deprived areas. Determining the interplay among race, socioeconomic status, area-level deprivation, and breast cancer survival may help identify intervention strategies to one day narrow the disparity gap.

Ground level
Given the findings that breast cancer survival among Black women may be associated with factors other than living in economically deprived neighborhoods, clinicians should consider other environmental factors when developing community-level approaches aimed at reducing these health disparities. The authors suggested that limited and delayed access to cancer screening and treatment in areas of greater deprivation may be another source of racial disparities in breast cancer mortality. They also suggested that implicit bias may be a factor contributing to late diagnoses and disparities in treatment for members of minority groups in the US and should be addressed.

Therapeutic Area

Archives

Matthew Gordon

VP, Real-World Evidence
Matthew has more than 25 years of experience in real-world evidence and observational, non-interventional research. He has led studies across the full life cycle—from startup through publication—supporting objectives that range from understanding a disease’s natural history to fulfilling global safety surveillance requirements. Matthew brings deep expertise in orphan disease programs, having overseen more than 25 long-term, global initiatives, as well as in disease and product registries, prospective pharmacoeconomic studies, and systematic literature reviews. Matthew leads the RWE Registries team, responsible for building the business and team. Prior to joining Aptitude Health, he held senior leadership roles at Parexel, Worldwide Clinical Trials, inVentiv Health Clinical, Quintiles Outcome, and ICON Clinical Research. Matthew holds a BA in sociology from Boston University, is a long-standing member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and is a frequent speaker at ISPOR, the Center for Business Intelligence, and related industry conferences.

Gerald Stanvitch, PhD

VP, Scientific Content

Cate Browning, PhD

VP, Global Medical Affairs

Erin Zingales Rau

VP, Account Services

Kelly Kocor

VP, People & Culture
Kelly leads both the human resources and talent acquisition teams, ensuring that Aptitude Health attracts, retains, and develops top personnel to drive our continued success. With over 17 years of experience transforming global HR initiatives, Kelly is an expert in harmonizing HR policies and fostering a culture of engagement and partnership. She is committed to partnering with all areas of the business to ensure full regulatory compliance and delivering value-added services to our organization and its people. Kelly is passionate about developing and implementing HR strategies that help support our employees’ professional and personal growth. She is dedicated to fostering a culture that encourages innovation, collaboration, and inclusivity, helping Aptitude Health continue to be a great place to work.

Bart Zygmond

VP, Finance
Bart brings a wealth of experience to the organization, having worked in the life sciences, pharmaceuticals, manufacturing, and service industries. With his expertise in financial reporting, US GAAP, SOX, cash flow modeling, and financial analysis, he plays a crucial role in the company’s financial management and strategy. Prior to joining Aptitude Health as VP, Finance, Bart held several controller positions: at Q2 Solutions, he oversaw the global finance team and financial operations, ensuring the accurate and timely financial reporting of the company. He also held controller positions at Domtar Inc and Veristat.

Eugene Vissers, MD

Senior VP, Global Scientific Content
Eugene is a seasoned medical doctor with over 20 years of international experience in pharma, consultancy, and agency environments. Eugene leads the US team of dedicated experts responsible for developing high-quality medical content. Prior to joining Aptitude Health, Eugene served as medical director at Ipsen and AstraZeneca. With both his medical degree and an MBA, Eugene brings a unique perspective to his role. His clinical background, combined with his business acumen, allows him to develop innovative strategies that drive results. Under Eugene’s leadership, the medical content team delivers scientific information of the highest quality, providing valuable insights to our clients around the world.

Adrian Barfield

VP, US Business Development

Kelley Hernandez

Executive VP, US Business Development
Kelley has over 18 years of experience in the oncology space. Kelley joined Aptitude Health after working with Cardinal Health, where she was part of the Healthcare and Analytics Division, and finished her tenure there with VitalSource™ (GPO division). As the leader of the strategic business development team for the US, Kelley brings a wealth of expertise to the organization. Her experience in the healthcare industry, combined with her ability to identify and capitalize on new business opportunities, is invaluable in driving the company’s growth and success. Kelley’s dedication to building strong relationships with life science partners is a testament to her commitment to delivering exceptional value to the healthcare industry.

Adam Sinensky, MBA

Chief Technology Officer

Adam has over 20 years of experience in the healthcare industry and an MBA in healthcare management. After 10 years as a strategy consultant to life science companies, Adam has spent the last decade as a product and strategy leader focused on bringing technology products to market across the payor, provider, and life sciences segments. By combining his business acumen and experience working directly with software developers, engineers, and data scientists, Adam has successfully led numerous product launches and enhancements from ideation to development and go-to-market initiatives. His product and change management expertise has led organizational shifts from services to technology at companies such as Change Healthcare and Datavant/Ciox. At Aptitude Health, Adam is responsible for growing our portfolio of product offerings by leveraging real-world data and artificial intelligence with our existing solutions and industry-leading Axess Network of healthcare providers. He also oversees our IT and cybersecurity teams.

Stefanie Daniels

Chief Commercial Officer

Stefanie is a seasoned healthcare executive with over 20 years of experience in oncology. She brings a wealth of knowledge and expertise to the organization. Stefanie joined Aptitude Health after spending over a decade as a senior director at Physicians’ Education Resource, an oncology CME vendor. During her tenure, she led and managed teams responsible for grant development/acquisition, program creation/execution, and faculty management. Stefanie’s deep understanding of the oncology industry and her ability to lead teams through complex projects make her a vital part of the organization’s success. Her dedication to providing high-quality solutions to our life science partners is a testament to her commitment to improving cancer patient care.

Jason Cash

Chief Financial Officer

Jason is an accomplished finance professional with over 20 years of experience in the pharmaceutical services industry. Throughout his career, he has demonstrated a keen ability to navigate high-growth organizations, delivering exceptional results. Before joining Aptitude Health, Jason served as the CFO of Veristat International, a global contract research organization. In this role, he led the financial strategy and played a pivotal role in driving the company’s growth and success. Jason’s wealth of experience and expertise in financial management make him an essential member of the leadership team. His strategic thinking and ability to drive results are highly respected within the industry.

Jez Moulding

Chief Executive Officer
Jez is a seasoned leader with over 20 years of experience in general management and regional president roles. He has a proven track record of success in the healthcare industry, having worked in the US, Japan, Australia, Korea, South Africa, France, and the UK for Sanofi, where he supported the launch of 10 new drugs across various therapeutic areas. As chief commercial officer at UDG Healthcare and EVP at Ashfield, Jez demonstrated his expertise in developing and implementing successful business strategies. He joined Aptitude Health from Pharmaspectra, an IQVIA business, where he served as CEO since 2018. Jez’s extensive experience in the pharmaceutical industry and his leadership skills make him an invaluable asset to the organization.